Aclaris Therapeutics, Inc. Severance Costs
Aclaris Therapeutics, Inc. (ACRS) reported Severance Costs of $2.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2026-02-26
- Aclaris Therapeutics, Inc. severance costs for the quarter ending 2024-12-31 was $100.00K.
- Aclaris Therapeutics, Inc. severance costs for the quarter ending 2024-09-30 was $26.00K.
- Aclaris Therapeutics, Inc. severance costs for the quarter ending 2024-06-30 was $100.00K.
- Aclaris Therapeutics, Inc. severance costs for the quarter ending 2024-03-31 was $2.50M.
- Aclaris Therapeutics, Inc. severance costs for fiscal 2024 was $2.70M.
- Aclaris Therapeutics, Inc. severance costs for fiscal 2020 was $100.00K, a 96.30% decline from fiscal 2019.
- Aclaris Therapeutics, Inc. severance costs for fiscal 2019 was $2.70M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month | Severance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $126.00K derived: sum of 2 quarters · filed 2026-02-26 | $226.00K derived: sum of 3 quarters · filed 2026-02-26 | $2.70M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $26.00K 10-Q · filed 2025-11-06 | $126.00K derived: sum of 2 quarters · filed 2025-11-06 | $2.60M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-07 | $2.60M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $2.50M 10-Q · filed 2025-05-08 | ||||
| 2020-12-31 | $100.00K 10-K · filed 2022-02-24 | ||||
| 2019-12-31 | $2.70M 10-K · filed 2022-02-24 | $2.75M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |